Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Cell International"
DOI: 10.1186/s12935-019-0836-8
Abstract: BackgroundLung cancer is one of the most common and deadly tumors around the world. Targeted therapy for patients with certain mutations, especially by use of tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR),… read more here.
Keywords: cell cycle; pc9gr; cancer; cell ... See more keywords